Today's RNS could be significant:

(strangely doesn't appear in MoneyAM's RNS lists!)

Here it is from the other place:

***************************************************

RNS Number:4181T
BioProjects International PLC
18 December 2003



BIOPROJECTS' MAIN INVESTMENT
PRODUCES DRAMATIC STUDY RESULTS

BioProjects International, the AIM-quoted company that invests in early-stage
biotechnology projects, today announces that the ViaLogy Corp, in which it has a
47.6 per cent stake, has completed a major research collaboration with its Swiss
partner, Zeptosens AG, which produced 'outstanding' results. The outcome is so
compelling that both companies have agreed to immediately initiate
commercialization.

The extensive research applied ViaLogy's Quantum Resonance Interferometry (QRI)
signal processing software to the planar waveguide (PWG) microarray technology
produced by Zeptosens AG of Switzerland. The study, using Zeptosens' high
sensitivity SensiChip microarray system, showed that QRI produced a 50-fold
improvement in the quantitation detection and a 10-fold reduction in data
variance.

This boost in performance opens the door for a level of in-depth information
detection and speed of screening in excess of any previously-known microarray
analysis. It will result in significant cost reductions as well as savings in
labour, time and information distortion.

"We are pleased with the outstanding results achieved by this collaboration with
Zeptosens," said Doug Lane, ViaLogy's CEO. "A 50-fold improvement is remarkable
and breaks new boundaries in detection and analysis."

The two companies will continue to integrate their technologies and next month
(January) ViaLogy plans to launch VMAxS, its ViaLogy Microarray Analysis
Service, which will be available to Zeptosens customers and others, on-line.

"We are delighted that ViaLogy has reached the stage where it is forming
Commercial alliances with such prestigious partners as Zeptosens," said
BioProjects' Chairman Jim Slater. "The technology is exciting and we believe it
will continue to make a real impact in the field of life sciences."

Further information from: Terry Bond, Managing Director, BioProjects
International.

Telephone 01235 834734 or mobile 07860 842756.
Email: terry.bond@bioprojects.com

***************************************************

Bioprojects' future is chiefly invested in this USA company (spun out from NASA). It is a compelling mix of leading edge computer and life sciences technology.

DYOR etc etc

Opening price 18/12/03 = 2.75p
RNS at 11.22am
Closing price 18/12/03 = 4.5p

http://www.bioprojects.com
http://www.vialogy.com
http://www.acolytebiomedica.com/index.htm
http://www.zeptosens.com/index2.html

Charts as follows:

Continuing my one man crusade on here:

Nice to see that the Swiss company (Zeptosens AG) with whom Vialogy is commercialising their DNA nicroarray tests received some recent funding from Novartis Pharma AG (a BIG company) and has therefore become an investor. I believe this adds credence to Vialogy's progress.

http://www.zeptosens.com/index2.html

Zeptosens successfully raises capital in series C financing round

WITTERSWIL, Oktober 2, 2003

Zeptosens AG, the Swiss bioanalytics company known for its high sensitivity DNA and protein microarray platform has successfully raised a significant seven-digit sum in CHF from Novartis Pharma AG.

"For us it is the confirmation that Zeptosens' outstanding products represent an attractive business case", says Dr. Markus Ehrat, CEO of Zeptosens AG. "We are very pleased to have one of the top ten pharmaceutical companies as one of our investors."

This money will enable Zeptosens to extend the application scope of its DNA and protein microarray platforms and thus provide efficient and high performance tools for the investigation and monitoring of cellular processes in life sciences.

Zeptosens develops and commercializes high-performance and high-throughput universal microarray platform comprises nanotechnology based, high sensitivity microarrays, readout systems and image analysis software for both gene and protein applications. The SensiChipTM product line demonstrates superior sensitivity and allowes users to detect genes so far not visible with other systems from less sample material. The ZeptoMARKTM protein microarray system is successfully applied for the investigation of biological pathways in drug development. It provides information faster and thus allows to expedite research and development processes.

This Wall Street Reporter interview is worth a listen to help understand Vialogy Corp a bit better (Bioprojects' main investment - 47.6% owned):

http://www.wallstreetreporter.com/profiles/ViaLogy.html

This Vialogy press release has only appeared today on the Vialogy website (albeit dated 6/1/04):

http://www.vialogy.com/press/pr013.html

Patent granted affecting application of quantum computing on protein arrays, etc

Presumably will be followed by a Bioprojects (BIP) RNS on Monday if material?

A big spread at the close (4.25 - 5.00) but technically 4.625p is a new closing high since just after the float in May 2002. I hope to see the bid move ahead tomorrow and a couple of high-volume closes above 4.75p would be nice to confirm that the rally has some serious puff to break out of the resistance area below 4.5p.

Hey Bones ! ADVFN has kicked me out or something. can't access the free BB's !

I'm in OK. lesk is posting that his AIMRaider handle has been locked out too. Maybe it's a bug?!

Do you have free access in ADVFN or paid ? Mine is free, dont know why I am locked out of FBB !!

Anyway BID at 5p now ! enjoy

I'm on free too. I suggest you email A...N.

As hoped, we have a strengthening bid on decent volumes. Hope to see a run to the old float price of 6p. Then there should be some mighty resistance from the institutions that subscribed and never saw that price again!

bones, mailed them. My userid had been banned :( !!!

BID at 5.5p :) Yipeeee

A nice finish today on increasing volumes. Approaching the original float price of 6p. It will be interesting to see how those original AIM subscribers cope with getting their money back. Will they sell out? Seems inevitable some will.

Bioprojects is up about 50% since start of Jan. Possible resistance at current price (c. 6p) due to that being the float price in 2002 and this is the first opportunity for subscribers to the float to exit with a small profit or breakeven. Some may feel tempted after nearly 2 years of paper losses!

I have taken profits on a quarter of my holding today at 6.125p in the light of this. I want to have a longer term holding but I expect to top-slice into strength.

One further good bit of news from Vialogy (BIP's main USA investment) should see the price clear of 6p.

I have sold some more at 5.5p for the same reasons mentioned above. Still hold a core investment which has been paid for from the profits.

Bones thanks for mentioning these had a good look at them and loved the Vialogy part of this.

"ViaLogy is providing a true technology shift in breakthrough performance capabilities for DNA microarrays, Protein arrays and other detection instruments by detecting signals that are up to four orders of magnitude lower than background noise --, results that can not be achieved by these devices today"

http://www.vialogy.com

Bought a few on the Vialogy bit alone happily I'm now in profit.

Cheers

Glad it is working out Janus! I have increased my holding again this week too! I would like to see the 7p area held early next week but a trace back to 6p would not be a surprise before we kick off again.

Regarding BIP, a poster elsewhere has flagged up a small mention in last Thursday's Guardian market summary:

http://www.guardian.co.uk/business/story/0,3604,1133557,00.html

"Among the smaller companies, dealers reported interest in Bioprojects, the Aim-listed investment vehicle set up by legendary financier Jim Slater to back promising biotech companies.

On that front City gossips believe one of its major investments, ViaLogy, is poised to float on Nasdaq. If the tittle-tattle is to be believed, then the valuation that ViaLogy will float at will make a mockery of BioProject's current market capitalisation. BioProject, up 11% to 6.25p yesterday, owns 48% of ViaLogy."

Taken profits on 50% of the holding today at 8.4p. The rest is running for no cost. Purely a risk adjustment in my pension fund.

Picked up a few again in the week at 8.1p and 8.7p. Just little top-ups.

Is commercial development coming closer at Acolyte? There are some new jobs being advertised here:

http://www.newscientistjobs.com/list/ViewJob-NS20042431039.html

I've lifted this from another BB (hot off the Californian presses!):

From Pasadena Star News Article Published: Saturday, February 07, 2004 - 1:22:46 PM PST

****************************************

Altadena firm may have found key to gene detection

ALTADENA -- If you've ever wondered whether high-tech companies really can make a difference, just ask Sandeep Gulati.
Imagine a cancer patient receiving nearly instantaneous, completely accurate test results within minutes of seeing a doctor. Or large pharmaceutical companies e-mailing blood sample data halfway across the world, just so they can obtain more conclusive results.
If Gulati is correct, you won't have to imagine much longer.
Gulati is the chief scientific officer and vice president of product development at ViaLogy Corp., an Altadena-based start-up that is bridging the gap between information technology and bioscience. Within 10 years, he predicts the company's DNA analysis software could completely overhaul the way doctors and scientists process biological information and treat all manners of disease.
"It allows you to handle biology at the molecular level,' Gulati said at the company's offices inside the Los Angeles County Business Technology Center. "It's a fundamental dynamic that could change this market overall.'
At its core, ViaLogy uses quantum resonance interferometry, a technology discovered at Caltech that allows scientists to pinpoint the information carried in a sample of DNA at up to 10,000 times the current standard of accuracy.
Once a blood sample is taken from a patient, it is then put onto a biochip. The chip transfers human data into a computerized format. It is then sent to ViaLogy, which claims it can locate 30 percent to 50 percent more data than other competing companies.
The sample, also called a microarray, projects thousands of electric signals. When a signal is found, researchers know another gene is present in the DNA.
"Really, it's about quality,' Gulati said. "Companies are made and unmade on that thesis.'
ViaLogy is moving fast to build on its patented technology. Chief Executive Doug Lane is leading a second round of private financing designed to raise between $10 million and $15 million to fund a 100- to 200-percent expansion of its 15-employee work force.
The expansion would enable the firm to grow its customer base at a much faster rate by applying more personnel to product production.
Current techniques may fail to detect as much as 70 percent of a sample's existing genes.
"The only way to determine early on if that target is optimal is the ability to understand every single gene in the process,' Lane said.
Lane sees no end to ViaLogy's possibilities. Since he joined the firm 2 1/2 years ago, Lane has led the start-up to the verge of profitability - all on the premise that ViaLogy's products could improve prospective new drugs' clinical success rate from 50 percent to 99.9 percent.
The CEO was convinced of ViaLogy's potential 15 minutes into his first interview at the firm.
"I didn't sleep for the first 30 days there,' he said. "It is truly a substantial discovery.'
Reactions to ViaLogy's claims have ranged from amazement to extreme skepticism, as private firms and the U.S. Food and Drug Administration grapple with the possibility that vastly improved gene detection could dramatically increase the presence of new drug therapies.
"First it's disbelief, then intense skepticism and scrutiny. Then it becomes, 'How do we get this?' ' Lane said.
One of the most serious challenges to the success of resonance interferometry has come from the FDA. Gulati said the agency does not accept microarray results when considering trial drugs for approval.
On Thursday, Lane returned from a several-day trip to Washington, D.C., where he lobbied agency officials for acceptance of the technology. If approved, it would open ViaLogy to a $2 billion gene analysis industry.
According to ViaLogy, interferometry could make the most impact on the pharmaceuticals industry, which uses microarrays more than any other group. Meanwhile, the company is already ramping up its online business, which allows it to accept data samples from across the globe while growing its core customer sales base. Current customers include high- tech mainstays Hewlett- Packard Co. and IBM.
-- Andrew Blazier can be reached at (626) 962-8811, Ext. 2477, or by e-mail at andrew.blazier@sgvn.com .

*****************************************

.

Progress announced on Acolyte Biomedica Ltd, including more external funding to assist with commercialisation of the MRSA rapid detector. Interesting that a Hong Kong based investor has emerged, what with SARS and all. Acolyte has the worldwide rights to so-called "AK Technology" (testing of bacteria in air) using the technology developed by the DSTL at Porton Down. Commercialisation is anticipated for end-2004.

Here is the RNS:

********************************
BioProjects International PLC
25 February 2004


BIOPROJECTS' INVESTMENT SECURES ADDITIONAL FUNDING

BioProjects International ('BioProjects' or 'the Company'), the AIM-quoted
company that provides capital and development advice for early-stage
biotechnology projects, announces that one of its major investments, Acolyte
Biomedica ('Acolyte'), has secured an additional 2.568m funding, with the
promise of a further 1.142m if required. It is expected that this will enable
the company to complete its research and development and commercialise its first
product in the near future.

The latest round of financing, which has been provided by a new investor, Circus
Capital of Hong Kong, and two existing investors, Partnerships UK and ANGLE
Technology, will initially be used to complete the development of technology
enabling the rapid identification of the MRSA bacteria, the hospital-acquired
infections that have been nicknamed 'Superbugs'. Acolyte's test aims to produce
reliable results within a two-to-four hour time period, which is a significant
reduction from current turnaround times of up to 48 hours. This will enable
hospitals to perform more comprehensive screening and thus reduce the spread of
infection. In the UK, hospital-acquired infections affect one hospital patient
in ten, costing 1 billion per annum.

The Acolyte product, BacLiteMRSA(R), is based upon technology originally
developed by Dstl, the research arm of the Ministry of Defence, at Porton Down,
for rapid detection of bacteria in air ('AK technology'). It will be the first
in a series of single organism tests. Acolyte is also developing rapid
antibiotic sensitivity tests to ensure patient infections are quickly identified
and treated with correct antibiotics. Acolyte has an exclusive, worldwide
licence to Dstl's IP estate in AK Technology for identification and antibiotic
resistance testing of microorganisms in medical diagnosis.
MRSA test results to date are described by the technical team as very positive
and the Department of Health-sponsored prototype to study the effects of rapid
MRSA testing is on track for delivery mid-year. The directors of Acolyte are
confident that the technology will be made commercially available to hospitals
by the end of the year.

'We are extremely pleased that Acolyte has secured this significant new
funding,' said BioProjects Chairman Jim Slater. 'When we first invested in the
company, three years ago, we did so because we believed the technology was sound
and that it could make a considerable contribution to healthcare world-wide.

'Acolyte is now in a position to complete its research and development and
commercialise its pipeline of products, the ultimate aim of every biotechnology
company.'

Terry Bond, Managing Director of BioProjects, has joined Julian Viggars,
BioProjects' and Partnership UK's joint representative, on the board of Acolyte.

Further information from: Terry Bond 01235 8343734
or 07860 842756


This information is provided by RNS
The company news service from the London Stock Exchange
********************************

It is good to see development of investments (other than Vialogy) held by BIP.